Golden dose Mounjaro – safety, myths and user changes

Does the "Golden dose" exist in Mounjaro?

No, there is no medically approved or intended “Golden dose” in a Mounjaro pen. The pen is designed to deliver a fixed number of preset doses, and only these doses are quality-assured. The concept originated in internet forums and lacks support in medical guidelines.

Mounjaro contains the active substance tirzepatide, a so-called dual agonist that affects both GLP-1 and GIP receptors and is used to regulate appetite and blood sugar. The medication is administered via a pre-filled multi-dose pen (KwikPen) and is usually administered once a week.

After the last intended dose, there may sometimes be visible liquid left in the pen. However, this does not correspond to a measured or quality-assured dose. Interpreting this residual liquid as an extra dose involves a risk of incorrect dosing and is not recommended.

Why is there Mounjaro left in the syringe if it is not to be used?

The liquid that may sometimes remain in a Mounjaro pen after completed use does not mean that there is an extra dose. The pen is designed to deliver a fixed number of preset doses with high precision, and only these doses are quality-assured.

The KwikPen contains a sufficient amount of the medicine to ensure correct use, including any priming before injection, as well as to deliver a total of four doses. The fact that there may be residual liquid is due to how the injection pen is designed to ensure that each regular dose can be given correctly throughout its entire use.

The remaining liquid therefore does not correspond to a measured or reliable dose and is not intended to be used.

Is it safe to use the "fifth dose" in a Mounjaro syringe?

No, it is not safe to attempt to use the residual liquid as an extra dose. Once the pen has delivered the intended number of doses, it is no longer designed or quality-assured for further use.

Attempting to extract residual liquid – for example, by trying to bypass the pen's function or using other methods – involves a risk of incorrect dosing. This can lead to both underdosing, with reduced treatment effect, and overdosing, with an increased risk of side effects.

At higher doses of tirzepatide, the most common side effects are gastrointestinal, such as nausea, vomiting, and diarrhoea. If these become pronounced, they can potentially lead to dehydration.

For safe and effective treatment, it is important that the medication is used as prescribed and that the dosage is not changed on your own.

What does science say about the "Golden dose" in Mounjaro?

There are no scientific studies or medical guidelines that support the use of a so-called “Golden dose” from a Mounjaro KwikPen. According to the official product information from the European Medicines Agency (EMA), the KwikPen is intended to deliver four fixed doses, and only these doses are approved and quality-assured within the scope of the intended use.

Use of remaining liquid after the intended doses therefore means that the amount of medication is not verified, which can affect both efficacy and safety. This is particularly important because tirzepatide is a potent medication where dosing in clinical studies and in clinical use is based on consistent and carefully defined delivery over time.

At Yazen, we work based on the principle of the lowest effective dose. This means that the dose is adjusted individually to provide a good effect on weight and appetite, while keeping the risk of side effects as low as possible. Using an uncontrolled amount of residual liquid on your own therefore goes against structured medical treatment.

Changes to the Mounjaro KwikPen – increased safety and reduced risk of misuse

Eli Lilly has introduced an updated version of the Mounjaro KwikPen which is being made gradually available globally during 2026. The changes apply to the injection pen itself and do not affect the medication's content, dosage, or treatment schedule.

The updated design aims to reduce the amount of remaining liquid in the pen as well as make it clearer when the fourth and final dose has been administered. Each KwikPen is still intended to deliver four fixed weekly doses and must be discarded after the fourth injection, even if a small amount of liquid remains.

The update aims to improve user-friendliness and clarity regarding when the pen is fully used. The modified construction should make it easier to see when the final dose has been given and reduces the risk of misunderstandings regarding any remaining liquid in the container.

It is important to emphasize that any residual liquid does not constitute an extra, controlled dose and should therefore not be used. The medication should always be administered as prescribed and according to current instructions to ensure safe and effective treatment.

Frequently Asked Questions about Mounjaro and dosing (FAQ)

Can I save the residual liquid from several pens and combine them?

No. It is not recommended to extract or save liquid from used injection pens to combine doses. This involves an increased risk of contamination and thus infection. Furthermore, it is not possible to ensure correct dosing, which can lead to both under- and overdosing as well as an increased risk of side effects. The medication should always be used as prescribed and in accordance with the manufacturer's instructions to ensure safe and effective treatment.

How do I dispose of a used Mounjaro pen that has liquid left?

Medication should not be flushed down the drain or thrown away with regular household waste. Consult a pharmacist on how to handle medications that are no longer used. Correct disposal helps to protect both the environment and human health.

What happens if I accidentally take too high a dose of Mounjaro?

If you have taken too high a dose of Mounjaro, you should immediately contact a doctor or healthcare services. An overdose can increase the risk of side effects, particularly nausea and vomiting. In some cases, low blood sugar (hypoglycaemia) may also occur, especially if the medication is used together with other blood sugar-lowering treatments.

Sources

European Medicines Agency (EMA). Mounjaro (tirzepatide) – EPAR Product Information.
https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro